Halozyme Therapeutics Inc. Common Stock (HALO)

About HALO

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as wel…

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Employees

423

Website

www.halozyme.com/

Fundamentals

1-day range

$90.5$103.29

Market cap

$10.17B

P/E (trailing)

27.63

P/E (forward)

9.92

EPS (trailing)

$3.35

Dividend yield

—

Beta

0.90

Avg. volume

1.99M

Forecasts

9 analyst ratings

Halozyme Therapeutics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• HALO

  Halozyme Therapeutics Inc. Common Stock

  $105.33

  ▼ 1.49%
  Market cap $10.17BP/E 27.63
  $61.23$109.66
• KYMR

  Kymera Therapeutics Inc. Common Stock

  $118.08

  ▼ 1.79%
  Market cap $8.75BP/E —
  $39.84$130.05
• QGEN

  Qiagen N.V. Common Shares

  $43.12

  ▼ 1.43%
  Market cap $8.60BP/E 22.14
  $32.53$57.82
• TWST

  Twist Bioscience Corporation Common Stock

  $141.16

  ▼ 7.80%
  Market cap $6.84BP/E —
  $23.3$155.44
• CRSP

  CRISPR Therapeutics AG Common Shares

  $57.69

  ▼ 2.84%
  Market cap $4.99BP/E —
  $44.12$78.48
• NBIX

  Neurocrine Biosciences Inc. Common Stock

  $153.98

  ▼ 1.24%
  Market cap $16.25BP/E 21.99
  $122.14$186.12
• RLAY

  Relay Therapeutics Inc. Common Stock

  $18.78

  ▼ 3.30%
  Market cap $3.78BP/E —
  $3.5$21.27

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Halozyme Therapeutics (NASDAQ:HALO) Meets Minervini’s High-Growth Trend Template
  ChartMill · 8/28/2026
• Watching Halozyme Therapeutics; Hearing Investor Business Daily SwingTrader Sells Stock
  benzinga · 8/25/2026
• Halozyme Therapeutics: Running Through 2027
  SeekingAlpha · 8/24/2026
• HALO Stock Rises 36% in a Month: Here's What You Should Know
  Yahoo · 8/21/2026
• Halozyme Therapeutics (NASDAQ:HALO) Demonstrates Strong Quality Investing Characteristics Across All Key Metrics
  ChartMill · 8/20/2026
• Halozyme Appoints Dannielle Appelhans to its Board of Directors
  Yahoo · 8/18/2026
• The Top 5 Analyst Questions From Halozyme Therapeutics’s Q2 Earnings Call
  Yahoo · 8/15/2026
• Incyte Corporation (INCY) has the Bigger Revenue Base, but Could Halozyme Therapeutics, Inc. (HALO) have the Better Economics?
  Yahoo · 8/14/2026
• Halozyme (HALO) Q2 2026 Earnings Call Transcript
  Yahoo · 8/13/2026

• Bernadette Connaughton · August 10, 2026 · Sale

  1.6K @ $102.8
• Helen Torley · July 8, 2026 · Option Exercise

  1.9K @ $12.07
• Helen Torley · July 8, 2026 · Sale

  1.0K @ $80.19
• Helen Torley · July 8, 2026 · Sale

  888 @ $79.28
• David A. Ramsay · July 1, 2026 · Grant

  39.8K
• David A. Ramsay · July 1, 2026 · Grant

  16.2K
• Snellgrove Darren · July 1, 2026 · Grant

  127.4K
• Snellgrove Darren · July 1, 2026 · Grant

  41.6K
• Bernadette Connaughton · July 1, 2026 · Sale

  625 @ $77.21
• Bernadette Connaughton · July 1, 2026 · Sale

  1.0K @ $76.4
• David A. Ramsay · June 30, 2026 · Option Exercise

  10.0K
• David A. Ramsay · June 30, 2026 · Tax Withholding

  5.4K @ $78.27
• Mark Howard Snyder · June 12, 2026 · Option Exercise

  5.0K
• Mark Howard Snyder · June 12, 2026 · Tax Withholding

  2.7K @ $69.5
• Helen Torley · June 3, 2026 · Option Exercise

  10.0K @ $12.07

Institutional Ownership

March 31, 2026

Total shares held

113.86M

Total value held

$7.04B

Institutional holders

622